Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases - PubMed (original) (raw)

Review

Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases

Gyun Jee Song et al. Front Aging Neurosci. 2017.

Abstract

Microglia are the resident innate immune cells of the central nervous system that mediate brain homeostasis maintenance. Microglia-mediated neuroinflammation is a hallmark shared by various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Numerous studies have shown microglial activation phenotypes to be heterogeneous; however, these microglial phenotypes can largely be categorized as being either M1 or M2 type. Although the specific classification of M1 and M2 functionally polarized microglia remains a topic for debate, the use of functional modulators of microglial phenotypes as potential therapeutic approaches for the treatment of neurodegenerative diseases has garnered considerable attention. This review discusses M1 and M2 microglial phenotypes and their relevance in neurodegenerative disease models, as described in recent literature. The modulation of microglial polarization toward the M2 phenotype may lead to development of future therapeutic and preventive strategies for neuroinflammatory and neurodegenerative diseases. Thus, we focus on recent studies of microglial polarization modulators, with a particular emphasis on the small-molecule compounds and their intracellular target proteins.

Keywords: microglial polarization; neurodegenerative diseases; neuroinflammation; neuroprotective; pharmacological modulator.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Abdel-Aleem G. A., Khaleel E. F., Mostafa D. G., Elberier L. K. (2016). Neuroprotective effect of resveratrol against brain ischemia reperfusion injury in rats entails reduction of DJ-1 protein expression and activation of PI3K/Akt/GSK3b survival pathway. Arch. Physiol. Biochem. 122 200–213. - PubMed
    1. Aguzzi A., Nuvolone M., Zhu C. (2013). The immunobiology of prion diseases. Nat. Rev. Immunol. 13 888–902. 10.1038/nri3553 - DOI - PubMed
    1. Bandyopadhyay G., Biswas T., Roy K. C., Mandal S., Mandal C., Pal B. C., et al. (2004). Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells. Blood 104 2514–2522. - PubMed
    1. Barad M., Bourtchouladze R., Winder D. G., Golan H., Kandel E. (1998). Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 95 15020–15025. - PMC - PubMed
    1. Batchelor P. E., Liberatore G. T., Wong J. Y., Porritt M. J., Frerichs F., Donnan G. A., et al. (1999). Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19 1708–1716. - PMC - PubMed

Publication types

LinkOut - more resources